Stemline Therapeutics (STML) Issues Quarterly Earnings Results, Misses Expectations By $0.06 EPS
Stemline Therapeutics (NASDAQ:STML) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06), Fidelity Earnings reports.
NASDAQ:STML opened at $13.20 on Friday. The firm has a market cap of $462.77 million, a P/E ratio of -4.49 and a beta of 0.58. Stemline Therapeutics has a 52-week low of $12.60 and a 52-week high of $20.55.
Several research firms recently issued reports on STML. ValuEngine lowered Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday. BidaskClub lowered Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday. Zacks Investment Research raised Stemline Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 16th. Finally, HC Wainwright set a $38.00 price objective on Stemline Therapeutics and gave the company a “buy” rating in a research note on Friday, August 10th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $30.00.
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Recommended Story: Bond
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.